What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Enzyme
His main research concerns Internal medicine, Endocrinology, Pharmacology, Pharmacokinetics and Cell biology.
He works mostly in the field of Internal medicine, limiting it down to topics relating to Cardiology and, in certain cases, Confidence interval and Mean arterial pressure.
His Endocrinology study frequently links to other fields, such as Odanacatib.
His Pharmacology research includes elements of Biomarker and Antibacterial agent.
His study in the fields of Cmax under the domain of Pharmacokinetics overlaps with other disciplines such as Raltegravir Potassium, Raltegravir and Integrase inhibitor.
The concepts of his Cell biology study are interwoven with issues in Neurite, Immunology and Fibroblast growth factor.
His most cited work include:
- Identification of a cyclic-AMP-responsive element within the rat somatostatin gene (1128 citations)
- Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity (1036 citations)
- Fit-for-purpose method development and validation for successful biomarker measurement. (589 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Pharmacology, Internal medicine, Pharmacokinetics, Endocrinology and Crossover study.
His work in the fields of Pharmacology, such as Tolerability and Pharmacodynamics, intersects with other areas such as Raltegravir.
Anacetrapib is the focus of his Internal medicine research.
He studied Pharmacokinetics and Sitagliptin that intersect with Dipeptidyl peptidase-4 inhibitor and Dipeptidyl peptidase-4.
His study explores the link between Endocrinology and topics such as Cell biology that cross with problems in Nerve growth factor and Biochemistry.
He has included themes like Anesthesia and Randomized controlled trial in his Crossover study study.
He most often published in these fields:
- Pharmacology (38.81%)
- Internal medicine (33.83%)
- Pharmacokinetics (31.34%)
What were the highlights of his more recent work (between 2012-2021)?
- Pharmacology (38.81%)
- Internal medicine (33.83%)
- Pharmacokinetics (31.34%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Pharmacology, Internal medicine, Pharmacokinetics, Endocrinology and Anacetrapib.
His work in the fields of Tolerability overlaps with other areas such as Midazolam.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His studies in Pharmacokinetics integrate themes in fields like Dyslipidemia, Adverse effect and Dosing.
His work in Endocrinology tackles topics such as Antigen presentation which are related to areas like Molecular biology.
His research in Anacetrapib tackles topics such as Atorvastatin which are related to areas like Apolipoprotein B, Metabolism and Statin.
Between 2012 and 2021, his most popular works were:
- Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir (64 citations)
- Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. (60 citations)
- Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects (58 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Enzyme
John A. Wagner mainly focuses on Internal medicine, Pharmacology, Pharmacokinetics, Endocrinology and Atorvastatin.
John A. Wagner performs multidisciplinary study in the fields of Internal medicine and Generalized estimating equation via his papers.
The study incorporates disciplines such as Boceprevir, Personalized medicine, Hepatitis C and Hepatitis C virus in addition to Pharmacology.
His Pharmacokinetics research incorporates elements of Gastroenterology and Needle biopsy.
He integrates Endocrinology and In patient in his research.
His study looks at the intersection of Atorvastatin and topics like Anacetrapib with Apolipoprotein B, Triglyceride and Total population.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
